Irene Koskan, MD
Internal Medicine · Bay St Louis, MSNPI 1831197862
Payments from drug & device makers
Across 300 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$960
- Amgen$813
- Novo Nordisk$802
- Lilly USA, LLC$576
- AstraZeneca$499
- Johnson & Johnson$462
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,202100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $960 |
| Amgen | 49 | $813 |
| Novo Nordisk | 28 | $802 |
| Lilly USA, LLC | 34 | $576 |
| AstraZeneca | 19 | $499 |
| Johnson & Johnson | 12 | $462 |
| Novartis | 30 | $444 |
| GSK | 17 | $365 |
| Pfizer | 13 | $242 |
| Mylan Specialty L.p. | 11 | $184 |
| Astellas Pharma US Inc | 5 | $172 |
| Sumitomo Pharma America, Inc. | 7 | $111 |
| Boehringer Ingelheim | 4 | $66 |
| BETA Bionics, Inc. | 2 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Abbott | 3 | $48 |
| Viatris Specialty LLC | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 3 | $41 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Dynavax Technologies Corporation | 1 | $27 |
| GE HealthCare | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Merz Pharmaceuticals, LLC | 1 | $22 |
| Merck | 1 | $21 |
| Impulse Dynamics (USA) Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| IBSA Pharma Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| PBG Puerto Rico LLC | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,216 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 71 | $100,016 |
| TrulicityDulaglutide | 61 | $97,674 |
| OzempicSemaglutide | 65 | $97,058 |
| FarxigaDapagliflozin Propanediol | 87 | $93,573 |
| EliquisApixaban | 103 | $74,109 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $72,158 |
| XareltoRivaroxaban | 62 | $64,246 |
| JardianceEmpagliflozin | 43 | $48,466 |
| MyrbetriqMirabegron | 25 | $28,989 |
| Repatha SureclickEvolocumab | 41 | $27,354 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $26,799 |
| LinzessLinaclotide | 26 | $26,039 |
| EntrestoSacubitril/Valsartan | 27 | $25,566 |
| GemtesaVibegron | 30 | $22,252 |
| VraylarCariprazine Hcl | 11 | $15,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $576 | $197,689132 claims |
| Novo NordiskOzempic | $802 | $97,05865 claims |
| AstraZenecaFarxiga | $499 | $93,57387 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $365 | $87,32693 claims |
| PfizerEliquis | $242 | $74,109103 claims |
| Johnson & JohnsonXarelto | $462 | $64,24662 claims |
| Boehringer IngelheimJardiance, Synjardy | $66 | $55,98755 claims |
| AbbVieLinzess, Vraylar, Synthroid | $960 | $44,039128 claims |
| Astellas Pharma US IncMyrbetriq | $172 | $28,98925 claims |
| NovartisEntresto | $444 | $25,56627 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $111 | $22,25230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Bay St Louis
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.